Flagship-founded Tessera plans to lay off 90 employees in March

The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz.

Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner MediLink Therapeutics for an ADC targeting the immune checkpoint protein.

Parabiosis Medicines raises $305 million to upend the status quo Biotech startup Parabiosis Medicines has raised $305 million in a Series A financing round led by ARCH Venture Partners, with participation from Perceptive Advisors and…

Ventyx has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion.

Alveus Therapeutics, which launched Thursday under the stewardship of former I-Mab CEO Raj Kannan, is hoping its development candidates can overcome pitfalls common to existing obesity medicines.

GSK has committed $50 million in upfront capital and near-term milestones to secure a license to two cancer research foundation models from Noetik.

Spiro Medical, which debuted last year, reeled in $67 million in series A funding it plans to use to develop its novel treatment for asthma.